Gandhinagar: The Gujarat headquartered Zydus group today announced its new brand identity with the listed entity of the group Cadila Healthcare Ltd to be known as Zydus Lifesciences Ltd. The company which has over 70 years of legacy said its new brand identity brings together two hearts in purple and teal colours symbolising its commitment to science and innovation alongwith care and nurturance. Pankaj R. Patel, Chairman, Zydus Lifesciences Ltd., said, “We have always believed in evolving ...Read More

Gandhinagar: Gujarat Chief Minister Bhupendra Patel today unveiled a 262 ft by 85 ft size art piece (Together We Fly) at Vaishno Devi circle on S.G. Highway here. The art piece is dedicated to corona warriors. DeshGujarat Gujarat CM unveils 262 by 85 ft size art piece dedicated to Covid warriors on SG Highway https://t.co/h9RMemqhS2 pic.twitter.com/tXRI2KuCLJ— DeshGujarat (@DeshGujarat) December 5, 2021 View this post on Instagram A post shared by DeshGujarat (@d...Read More

Gandhinagar(Press release) Zydus Cadila, an innovation-driven, global pharmaceutical company, today announced that it has submitted the New Drug Application (NDA) to the Drug Controller General of India for Desidustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for treatment of anaemia in patients with Chronic Kidney Disease (CKD) who are on Dialysis and Not on Dialysis. Chronic Kidney Disease is a serious progressive medical condition which is a glo...Read More

New DelhiL Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D today i.e 20/08/2021, the world’s first and India’s indigenously developed DNA based vaccine for COVID-19 to be administered in humans including Children and adults 12 years and above. Developed in partnership with the Department of Biotechnology, Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, ZyCoV-D has been s...Read More

Gandhinagar: Zydus Cadila today announced that its biological therapy ZRC-3308, a cocktail of two SARS-CoV-2-neutralizing monoclonal antibodies (mAbs) can emerge as one of the main treatments for mild COVID 19. SARS-CoV-2 spike protein targeted, neutralizing monoclonal antibody based treatments have received emergency use authorization in mild COVID 19 in the US, Europe and in India because they significantly reduced viral load in mild patients and their rate of hospitalization. Two of these pr...Read More

Ahmedabad (Press Statement): Zydus, an innovation driven global pharma major and TLC, a specialty pharmaceutical company in Taiwan, today announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ (Amphotericin B Liposome for Injection 50mg) in India. AmphoTLC™ is a critical drug to treat Mucormycosis or Black Fungus in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC™ on a non-exclusive basis to Zyd...Read More

Ahmedabad: Managing Director of Zydus Dr. Sharvil Patel today said: The clinical trial phase of Zydus vaccine against Covid19 is over. Our vaccine had largest clinical study on Indian population covering over 28,000 patients. We have covered all groups including those above 60-75 years age, comorbid young ones and even 12-18 years children. We expect efficacy results to be out in the month of May this year and then we will apply with DCGI for emergency use approval. We have given lot of data to...Read More

Ahmedabad: Managing Director of Zydus Cadila today said company's upcoming Virafin medicine will be out in ten days for selective covid treating facility. It will be available in large number for wider consumption after 45 days. On Virafin: Virafin is interferon injection which is known as anti viral drug. Worldwide it has been used for hepatitis B, hepatitis C and other viruses. It neutralizes virus and prevent its replication and helps the body for viral clearance. Its single dose has to...Read More

Gandhinagar: Zydus Cadila today announced that the company has received Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults. A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the c...Read More